Prevalence and control of hypercholesterolaemia as defined by NCEP-ATPIII guidelines and predictors of LDL-C goal attainment in a multi-ethnic asian population

Annals of the Academy of Medicine Singapore

Volumn 42, Issue 8, 2013, Pages 379-387

  Khoo, Chin Meng ^a,e   Tan, Maudrene L S ^b   Wu, Yi ^b   Wai, Daniel C H ^c   Subramaniam, Tavintharan ^d   Tai, E Shyong ^a,b,e   Lee, Jeannette ^b  

^a Dept Medicine Endocrinol Diabet   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d KHOO TECK PUAT HOSPITAL   (Singapore)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Asians; Awareness; Cholesterol; Goal attainment; Prevalence ratio; Treatment

Indexed keywords

ATORVASTATIN; CHOLESTEROL; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ASIAN; AWARENESS; BODY MASS; CARDIOVASCULAR RISK; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE CONTROL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE MODIFICATION; MALE; NATIONAL CHOLESTEROL EDUCATION PROGRAM ADULT TREATMENT PANEL III GUIDELINES; PRACTICE GUIDELINE; PREVALENCE; QUESTIONNAIRE; SMOKING CESSATION; SOCIAL CLASS;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; SINGAPORE; YOUNG ADULT;

EID: 84883469935     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation 2008;118:2702-9.
2. Zhang X, Patel A, Horibe H, Wu Z, Barzi F, Rodgers A, et al. Cholesterol, coronary heart disease, and stroke in the Asia Pacific region. Int J Epidemiol 2003;32:563-72.
3. Critchley J, Liu J, Zhao D, Wei W, Capewell S. Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation 2004;110:1236-44.
4. Wijeysundera HC, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. JAMA 2010;303:1841-7.
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
6. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-57.
7. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
8. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet 2002;360:7-22.
9. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
10. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
11. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45.
12. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
13. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
14. Kim HS, Wu Y, Lin SJ, Deerochanawong C, Zambahari R, Zhao L, et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITYAsia) study. Curr Med Res Opin 2008;24:1951-63.
15. Nang EE, Khoo CM, Tai ES, Lim SC, Tavintharan S, Wong TY, et al. Is there a clear threshold for fasting plasma glucose that differentiates between those with and without neuropathy and chronic kidney disease?: the Singapore Prospective Study Program. Am J Epidemiol 2009;169:1454-62.
16. Cutter J, Tan BY, Chew SK. Levels of cardiovascular disease risk factors in Singapore following a national intervention programme. Bull World Health Organ 2001;79:908-15.
17. Hughes K, Aw TC, Kuperan P, Choo M. Central obesity, insulin resistance, syndrome X, lipoprotein(a), and cardiovascular risk in Indians, Malays, and Chinese in Singapore. J Epidemiol Community Health 1997;51:394-9.
18. Hughes K, Yeo PP, Lun KC, Thai AC, Sothy SP, Wang KW, et al. Cardiovascular diseases in Chinese, Malays, and Indians in Singapore. II. Differences in risk factor levels. J Epidemiol Community Health 1990;44:29-35.
19. Tan CE, Emmanuel SC, Tan BY, Jacob E. Prevalence of diabetes and ethnic differences in cardiovascular risk factors. The 1992 Singapore National Health Survey. Diabetes Care 1999;22:241-7.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
21. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
22. Wu YF. [The second multi-center survey of dyslipidemia management in China: goal attainment rate and related factors]. Zhonghua Xin Xue Guan Bing Za Zhi 2007;35:420-7.
23. Clearfield MB. Underidentification and undertreatment of dyslipidemia. J Am Osteopath Assoc 2003;103:S5-8.
24. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving lowdensity lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
25. Mak KH, Chia KS, Kark JD, Chua T, Tan C, Foong BH, et al. Ethnic differences in acute myocardial infarction in Singapore. Eur Heart J 2003;24:151-60.
26. Hyre AD, Muntner P, Menke A, Raggi P, He J. Trends in ATP-III-defined high blood cholesterol prevalence, awareness, treatment and control among U.S. adults. Ann Epidemiol 2007;17:548-55.
27. Tay JC, Chee YC. Drug treatment of hypercholesterolaemia. Ann Acad Med Singapore 1998;27:794-9.
28. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother 2008;42:1208-15.
29. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure: factors associated with lack of blood pressure control in the community. Hypertension 2000;36:594-9.
30. Krauss RM, Winston M, Fletcher BJ, Grundy SM. Obesity: impact on cardiovascular disease. Circulation 1998;98:1472-6.
31. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ 1989;298:784-8.
32. Kim BJ, Hwang ST, Sung KC, Kim BS, Kang JH, Lee MH, et al. Comparison of the relationships between serum apolipoprotein B and serum lipid distributions. Clin Chem 2005;51:2257-63.
33. McGill HC, Jr., McMahan CA, Malcom GT, Oalmann MC, Strong JP. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol 1997;17:95-106.
34. Hozawa A, Folsom AR, Sharrett AR, Payne TJ, Chambless LE. Does the impact of smoking on coronary heart disease differ by low-density lipoprotein cholesterol level?: the Atherosclerosis Risk in Communities (ARIC) Study. Circ J 2006;70:1105-10.
35. Paeratakul S, Lovejoy JC, Ryan DH, Bray GA. The relation of gender, race and socioeconomic status to obesity and obesity comorbidities in a sample of US adults. Int J Obes Relat Metab Disord 2002;26:1205-10.
36. Standridge JB, Zylstra RG, Adams SM. Alcohol consumption: an overview of benefits and risks. South Med J 2004;97:664-72.
37. Konig D, Deibert P, Winkler K, Berg A. Association between LDLcholesterol, statin therapy, physical activity and inflammatory markers in patients with stable coronary heart disease. Exerc Immunol Rev 2005;11:97-107.
38. Gallo LC, Troxel WM, Kuller LH, Sutton-Tyrrell K, Edmundowicz D, Matthews KA. Marital status, marital quality, and atherosclerotic burden in postmenopausal women. Psychosom Med 2003;65:952-62.
39. Erem C, Hacihasanoglu A, Deger O, Kocak M, Topbas M. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine 2008;34:36-51.
40. Fletcher B, Berra K, Ades P, Braun LT, Burke LE, Durstine JL, et al. Managing abnormal blood lipids: a collaborative approach. Circulation 2005;112:3184-209.
41. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992;56:320-8.
42. Bookstein L, Gidding SS, Donovan M, Smith FA. Day-to-day variability of serum cholesterol, triglyceride, and high-density lipoprotein cholesterol levels. Impact on the assessment of risk according to the National Cholesterol Education Program guidelines. Arch Intern Med 1990;150:1653-7.
43. Goff DC, Jr., Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 2006;113:647-56.